These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 57335)

  • 1. Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse.
    Alberts DS; Durie BG; Salmon SE
    Lancet; 1976 May; 1(7966):926-8. PubMed ID: 57335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrosoureas in multiple myeloma.
    Salmon SE
    Cancer Treat Rep; 1976 Jun; 60(6):789-94. PubMed ID: 782701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.
    Alberts DS; Salmon SE
    Cancer Chemother Rep; 1975; 59(2 Pt 1):345-50. PubMed ID: 1097093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
    Presant CA; Klahr C
    Cancer; 1978 Sep; 42(3):1222-7. PubMed ID: 698913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
    Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of plasma cell myeloma with cytotoxic agents.
    Bergsagel DE; Pruzanski W
    Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy for multiple myeloma.
    Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet JD; Alexanian R; Salmon SE; Haut A; Dixon DO
    Cancer Treat Rep; 1984 Mar; 68(3):481-5. PubMed ID: 6200220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B; Smith L; Alexanian R
    N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of plasma cell myeloma.
    Bergsagel DE
    Br J Haematol; 1976 Aug; 33(4):443-9. PubMed ID: 795453
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
    Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
    Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia.
    Presant CA; Klahr C; Santala R
    Ann Intern Med; 1977 Jan; 86(1):47-51. PubMed ID: 264783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.
    Cooper MR; McIntyre OR; Propert KJ; Kochwa S; Anderson K; Coleman M; Kyle RA; Prager D; Rafla S; Zimmer B
    J Clin Oncol; 1986 Sep; 4(9):1331-9. PubMed ID: 3528403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.